cladribine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, DH; Boulet, A; Hammond, SA; Kendall, S; Mellor, P; Plaza, K; Plett, R; Vizeacoumar, FJ; Vizeacoumar, FS | 1 |
1 other study(ies) available for cladribine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Doxorubicin; Excipients; Homoharringtonine; Humans; Nucleosides; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |